151 related articles for article (PubMed ID: 26741162)
61. Enzyme responsiveness enhances the specificity and effectiveness of nanoparticles for the treatment of B16F10 melanoma.
Huang Y; Shi Y; Wang Q; Qi T; Fu X; Gu Z; Zhang Y; Zhai G; Zhao X; Sun Q; Lin G
J Control Release; 2019 Dec; 316():208-222. PubMed ID: 31682909
[TBL] [Abstract][Full Text] [Related]
62. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes.
Campbell RB; Balasubramanian SV; Straubinger RM
J Pharm Sci; 2001 Aug; 90(8):1091-105. PubMed ID: 11536214
[TBL] [Abstract][Full Text] [Related]
63. Para amino benzoic acid-derived self-assembled biocompatible nanoparticles for efficient delivery of siRNA.
Reddy TL; Krishnarao PS; Rao GK; Bhimireddy E; Venkateswarlu P; Mohapatra DK; Yadav JS; Bhadra U; Bhadra MP
Int J Nanomedicine; 2015; 10():6411-23. PubMed ID: 26491299
[TBL] [Abstract][Full Text] [Related]
64. Zwitterionic-to-cationic charge conversion polyprodrug nanomedicine for enhanced drug delivery.
Wang S; Zhang F; Yu G; Wang Z; Jacobson O; Ma Y; Tian R; Deng H; Yang W; Chen ZY; Chen X
Theranostics; 2020; 10(15):6629-6637. PubMed ID: 32550894
[TBL] [Abstract][Full Text] [Related]
65. Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy.
Ananta JS; Paulmurugan R; Massoud TF
Mol Pharm; 2016 Sep; 13(9):3164-75. PubMed ID: 27508339
[TBL] [Abstract][Full Text] [Related]
66. Electroneutral composite polymersomes self-assembled by amphiphilic polyphosphazenes for effective miR-200c in vivo delivery to inhibit drug resistant lung cancer.
Peng Y; Zhu X; Qiu L
Biomaterials; 2016 Nov; 106():1-12. PubMed ID: 27541441
[TBL] [Abstract][Full Text] [Related]
67. Catanionic Hybrid Lipid Nanovesicles for Improved Bioavailability and Efficacy of Chemotherapeutic Drugs.
Xie X; He D; Wu Y; Wang T; Zhong C; Zhang J
Methods Mol Biol; 2021; 2211():57-68. PubMed ID: 33336270
[TBL] [Abstract][Full Text] [Related]
68. Platinated graphene oxide: A nanoplatform for efficient gene-chemo combination cancer therapy.
Liu P; Wang S; Liu X; Ding J; Zhou W
Eur J Pharm Sci; 2018 Aug; 121():319-329. PubMed ID: 29906508
[TBL] [Abstract][Full Text] [Related]
69. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.
Cheng X; Lee RJ
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):129-137. PubMed ID: 26900977
[TBL] [Abstract][Full Text] [Related]
70. Cationic lipid-based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effects.
Brody LP; Sahuri-Arisoylu M; Parkinson JR; Parkes HG; So PW; Hajji N; Thomas EL; Frost GS; Miller AD; Bell JD
Int J Nanomedicine; 2017; 12():6677-6685. PubMed ID: 28932113
[TBL] [Abstract][Full Text] [Related]
71. Tailoring the lipid composition of nanoparticles modulates their cellular uptake and affects the viability of triple negative breast cancer cells.
Abumanhal-Masarweh H; da Silva D; Poley M; Zinger A; Goldman E; Krinsky N; Kleiner R; Shenbach G; Schroeder JE; Shklover J; Shainsky-Roitman J; Schroeder A
J Control Release; 2019 Aug; 307():331-341. PubMed ID: 31238049
[TBL] [Abstract][Full Text] [Related]
72. pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model.
Zhang YJ; Zhan X; Wang L; Ho RJ; Sasaki T
J Pharm Sci; 2015 May; 104(5):1815-24. PubMed ID: 25753991
[TBL] [Abstract][Full Text] [Related]
73. Preparation, characterization, and evaluation of antitumor effect of Brucea javanica oil cationic nanoemulsions.
Liu TT; Mu LQ; Dai W; Wang CB; Liu XY; Xiang DX
Int J Nanomedicine; 2016; 11():2515-29. PubMed ID: 27330293
[TBL] [Abstract][Full Text] [Related]
74. Targeted Delivery of miRNA 155 to Tumor Associated Macrophages for Tumor Immunotherapy.
Zang X; Zhang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D
Mol Pharm; 2019 Apr; 16(4):1714-1722. PubMed ID: 30860846
[TBL] [Abstract][Full Text] [Related]
75. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma.
Zhang M; Zhou X; Wang B; Yung BC; Lee LJ; Ghoshal K; Lee RJ
J Control Release; 2013 Jun; 168(3):251-61. PubMed ID: 23567045
[TBL] [Abstract][Full Text] [Related]
76. Cationic lipid bioanalysis: understanding distribution of lipid nanoparticles for delivery of RNA therapeutics.
Hawthorne G; Harbach S; Wilson A
Bioanalysis; 2018 Mar; 10(5):275-277. PubMed ID: 29494232
[No Abstract] [Full Text] [Related]
77. Ionizable lipid nanoparticles for RAS protease delivery to inhibit cancer cell proliferation.
Atsavapranee E; Haley RM; Billingsley MM; Chan A; Ruan B; Figueroa-Espada CG; Gong N; Mukalel AJ; Bryan PN; Mitchell MJ
J Control Release; 2024 Jun; 370():614-625. PubMed ID: 38729436
[TBL] [Abstract][Full Text] [Related]
78. Immune modulatory nanoparticle therapeutics for intracerebral glioma.
Yaghi NK; Wei J; Hashimoto Y; Kong LY; Gabrusiewicz K; Nduom EK; Ling X; Huang N; Zhou S; Kerrigan BC; Levine JM; Fajt VR; Levine G; Porter BF; Marcusson EG; Tachikawa K; Chivukula P; Webb DC; Payne JE; Heimberger AB
Neuro Oncol; 2017 Mar; 19(3):372-382. PubMed ID: 27765835
[TBL] [Abstract][Full Text] [Related]
79. Topical Lyophilized Targeted Lipid Nanoparticles in the Restoration of Skin Barrier Function following Burn Wound.
Li J; Ghatak S; El Masry MS; Das A; Liu Y; Roy S; Lee RJ; Sen CK
Mol Ther; 2018 Sep; 26(9):2178-2188. PubMed ID: 29802017
[TBL] [Abstract][Full Text] [Related]
80. Evaluation of MicroRNA Delivery In Vivo.
Brown RAM; Richardson KL; Kalinowski FC; Epis MR; Horsham JL; Kabir TD; De Pinho MH; Beveridge DJ; Stuart LM; Wintle LC; Leedman PJ
Methods Mol Biol; 2018; 1699():155-178. PubMed ID: 29086376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
